quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 16, 2026

Starbucks Corporation Announces Early Results and Upsizing of its Tender Offers for Eight Series of Notes

View original at finance.yahoo.com
“4.500% Senior Notes due 2028 [CUSIP 855244BN8] Aggregate Principal Amount Outstanding: $750,000,000”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • $2,598,857,000 aggregate principal amount of the Notes were validly tendered prior to or at 5:00 p.m. Eastern Time on May 15, 2026 and not validly withdrawn

    60% confidence
  • The 4.500% Senior Notes due 2048 are subject to an aggregate principal amount sublimit of $200,000,000

    60% confidence
  • Except as described in the May 16 press release, the terms and conditions of the Tender Offers set forth in the Offer to Purchase remain unchanged

    60% confidence
  • Because the aggregate purchase price of tendered Notes exceeds the Aggregate Cap and Maximum Amounts, Starbucks does not expect to accept any further tenders of Notes

    60% confidence
  • Starbucks increased the Aggregate Cap for all Notes to $1.3 billion, the Pool 1 Maximum Amount to $600 million, and the Pool 2 Maximum Amount to $700 million

    60% confidence

Data points we hold from this source

Starbucks Corporation · principal tendered2598857000 USD
Starbucks Corporation · debt5000000000 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com